{"organizations": [], "uuid": "992090c5e1ea2d7e359899673225e9fafcf9dcb7", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180306.html", "section_title": "Archive News &amp; Video for Tuesday, 06 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-bavarian-nordic-additional-positiv/brief-bavarian-nordic-additional-positive-data-from-phase-2-study-idUSASM000K4T", "country": "US", "domain_rank": 408, "title": "BRIEF-Bavarian Nordic: Additional Positive Data From Phase 2 Study", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.497, "site_type": "news", "published": "2018-03-06T21:43:00.000+02:00", "replies_count": 0, "uuid": "992090c5e1ea2d7e359899673225e9fafcf9dcb7"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-bavarian-nordic-additional-positiv/brief-bavarian-nordic-additional-positive-data-from-phase-2-study-idUSASM000K4T", "ord_in_thread": 0, "title": "BRIEF-Bavarian Nordic: Additional Positive Data From Phase 2 Study", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 6 (Reuters) - BAVARIAN NORDIC A/S:\n* REG-BAVARIAN NORDIC ANNOUNCES ADDITIONAL POSITIVE DATA FROM A PHASE 2 STUDY OF ITS UNIVERSAL RSV VACCINE\n* SAYS TODAY ANNOUNCED ADDITIONAL POSITIVE DATA FROM ITS 421 PATIENT\n* ‍PRESENCE OF ANTIBODIES IN NASAL MUCOSA SUGGEST VACCINE-INDUCED IMMUNE PROTECTION AT SOURCE OF INFECTION​\n* ‍IGA ANTIBODIES AGAINST RSV OBSERVED IN BOTH SERUM AND MUCOSA OF VACCINATED INDIVIDUALS​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-06T21:43:00.000+02:00", "crawled": "2018-03-07T19:52:54.004+02:00", "highlightTitle": ""}